Objective: The main objective is to describe and analyse hospital costs of the extracorporeal membrane oxygenation (ECMO) procedure. Study sample and methodology: Between January and December 2007, 14 ECMO patients were consecutively included in the study. Costs at the patient level were registered prospectively, while overhead costs were registered retrospectively. Patient costs were obtained from patient records and time-motion studies and included personnel resources, diagnostic and laboratory tests, radiology and operating room procedures, medication and blood products. Overhead costs were allocated to clinical departments and further to the individual patients by predefined keys. To achieve estimates of total costs, patient-specific costs and patient-specified overhead costs were summarised. Results: The mean estimated cost for the ECMO procedure was 73,122 USD (SD 34,786) and median 62,545 USD (range: 34,121-154,817). The mean estimated total hospital costs, including pre-and post-ECMO procedures, was 213,246 USD (SD 12,265), median 191,436 USD (range: 59,497). On average, 82% of costs for the total hospital stay were related to personnel use, and blood products constituted 7%, lab and radiology 2.5%, disposable items 3% and medication 1.5%. The mean duration of an ECMO procedure was 9.5 days (range: 4-23 days) and the average total length of stay in hospital was 51.5 days (range: 6-123 days). The cost data were converted from Norwegian kroner (NOK) to US dollars (USD), with an exchange rate of 1 USD = 5.5 NOK. Conclusion: ECMO procedure is a resource-demanding procedure. #
Introduction
Extracorporeal membrane oxygenation (ECMO) is a technique for providing life support to patients suffering from severe, but reversible, pulmonary and/or cardiac failure. It is an expensive procedure with significant complications, but with a high survival rate justifying its increasing use in the western world [1] [2] [3] [4] [5] .
ECMO is a simplified version of the heart-lung machine. The first successful ECMO treatment was performed in 1971 by Donald Hill [6] . In 1975, Robert Bartlett reported the first ECMO survival in a neonate; a newborn baby with meconium aspiration [7] .
ECMO may be used in neonatal, paediatric and adult patients with pulmonary or circulatory failure, who are unresponsive to conventional therapy. ECMO may be used as a bridge to recovery, and for heart failure, also as a bridge to transplantation or to a long-term assist device. ECMO was established at the Rikshospitalet University Hospital in 1990 to support patients with acute life-threatening pulmonary failure and, in 1993, was also extended to support patients with heart failure (cardiac ECMO).
Study sample and methodology

Patients and procedures
The study includes 15 consecutive ECMO procedures performed in 14 patients (nine men and five women) at the Rikshospitalet University Hospital, Oslo, from January through December 2007. One patient was on ECMO twice during one hospital stay. Six patients were treated for respiratory and eight for cardiac failure. Four patients were younger than 1 month at the time of treatment. Patient characteristics and indications for ECMO are presented in Table 1 .
Surgical technology
Two patients had venovenous ECMO procedures (VV-ECMO) and 13 had venoarterial ECMO (VA-ECMO). One patient had two venoarterial procedures. Further details regarding the centrifugal pump ECMO procedure used at our hospital have been described by Pedersen and colleagues [8] . The ECMO cannulas were inserted percutaneously into the femoral artery and vein by the Seldinger technique in nine patients. In four patients, a cut-down technique (neck cannulation of carotid artery and jugular vein) was used. In two patients, direct cannulation (of the heart after open heart surgery) was used. In all cases, Bio-Medicus cannulas were implemented. QUADROX D membrane oxygenators (Malquet Cardiopulmonary AG, Hiarlingen, Germany) were used in adults, and Minimax Plus (Medtronic Bio-Medicus Inc., Eden Prairie, MN, USA) or Lilliput 2 (Dideco D 902 Infant Hollow Fibre Membrane Oxygenator, Italy) was used in neonates and smaller children.
Two patients were treated with an intra-aortic balloon pump (IABP). All surgical procedures were performed under general anaesthesia. Prior to and during ECMO treatment, all patients were on conventional ventilators and sedated with infusions of opiates and midazolam.
Cost analysis
The focus for the cost analysis was the Rikshospitalet University Hospital; hence only the costs incurred at this hospital were considered, implying that the costs incurred at secondary and local hospitals and transport are not included.
We have some indications that these costs are relatively low and unlikely to affect the results of the analysis significantly. The costs at the patient level were registered prospectively, while overhead costs were registered retrospectively. Patient costs were obtained from patient records and timemotion studies and included personnel resources, diagnostic and laboratory tests, radiology and operating room procedures, medication and blood products. Overhead costs were allocated to clinical departments and further to the individual patients by predefined keys. To estimate the total costs incurred, patient-specific costs and patient-specified overhead costs were summarised.
The costs in the ICU were calculated in two different ways. First, to calculate what is called the basic ICU cost per day, total running cost data were obtained from the ICU's financial results from FY 2006, adjusted for price changes and divided by the total number of patient-days in the ICU. Second, since ECMO patients were more resource demanding than average ICU patients, data on excess resource use were collected. These costs included resources such as physicians, anaesthesiologists, perfusionists, respiratory physiotherapists and other actual staff members who were not included in the basic ICU costs. Costs generated by their contribution (additional ECMO costs) were consequently added to the basic ICU costs to obtain the total ICU costs during the ECMO procedure.
The cost analysis approach implies that the costs of each ECMO procedure include the main resource variables such as ICU stay, additional costs at ICU, OR costs, drugs, blood products, lab and radiology services and disposable equipment [9] [10] [11] [12] [13] . To calculate the total hospital costs, resources related to pre-and post-ECMO stay were added. Some patients had longer hospital stay prior to and after the ECMO procedure and underwent other procedures during their hospital stay that contributed to higher total hospital costs.
All costs were calculated at 2007 prices in Norwegian kroner (NOK) and converted to US dollars (USD), with the exchange rate of 1 USD = 5.5 NOK. 
Results
The average duration of the ECMO was 9.5 days (range: 4-23 days), of which almost all days were ICU days. The mean length of stay at hospital was 51.5 days (range: 6-123 days). The ICU stay constituted the main part of the total length of hospital stays, with an average of 32.8 days (range: 0-88 days) ( Table 2) .
The mean and median values for total hospital costs, including pre-and post-ECMO stays and procedures, were 210,142 USD (SD 12,265) and 191,436 USD (range: 59,871-405,497), respectively. The mean and median costs for the ECMO procedure were 73,122 USD (SD 34,786) and 62,545 USD (range: 34,121-154,817 USD) (Fig. 1) . Further analysis showed that the ECMO procedure accounted for additional cost in the ICU (average 67,000 USD), majority of the additional costs being related to personnel such as physicians, perfusionists, anaesthesiologists, physiotherapists and ICU nurses. A break up of cost drivers shows that, of the total hospital costs, staff constituted 82%, blood products 7%, lab and radiology 2.5%, disposable items 3% and drugs 1.5%.
Of the 14 patients, eight could be successfully weaned from ECMO, three were bridged to another assist device, one underwent a heart transplant, whereas two patients died during ECMO. A total of three patients died within 30 days, thus the early mortality rate was 21.4%.
Three patients died during follow-up (range: 0-2.3 years, mean 1.9 years), and eight of the 14 patients (57.1%) are still alive. The most frequent complications were bleeding (10 patients), renal failure (six patients), pneumonia (four patients) and stroke (one patient).
Discussion
Our main objective was to describe and analyse the hospital costs of the ECMO procedure, both ECMO procedure costs and total hospital costs for ECMO patients, from a hospital perspective. Our main results -that an average ECMO procedure costs 73,122 USD and that an average ECMO patient had a total hospital cost of 210,142 USDdemonstrate that ECMO is a highly resource-demanding procedure.
The major portion of the costs is related to treatment in the intensive care unit (ICU). This is not surprising as ICUs in general are characterised by use of sophisticated diagnostic and life-support technology and represent the maximum cost driver, up to one-third the total cost, in hospitals [14, 15] . The complexity of ECMO patients requires a team approach in the ICU [16] , which drives up costs additionally. At our centre, the team consisted of physicians, perfusionists, surgeons, anaesthesiologist, nurses and physiotherapists.
It is very difficult to compare the ICU costs in this analyses with that from other centres due to variation in costing methods and different patient mix [17] [18] [19] [20] [21] . However, several studies have shown that ECMO procedures are highly resource demanding but significantly improve survival rate and quality of life [22] [23] [24] . A study by Petrou and colleagues [25] analysed the long-term cost-effectiveness of ECMO for mature newborn infants presenting severe respiratory failures. The average cost for the first 7 years of life was £30,270 for the ECMO group and £10,229 for the conventional management group. Another study by Angus and colleagues [26] showed that costs increased significantly for those needing ECMO treatment (mean cost $55,711 vs $44,461).
Besides, Norway has only 4.7 million inhabitants and, consequently, has few patients requiring this type of care; therefore, the high costs of the ECMO procedure and, more generally, fewer numbers of ECMO patients are the main arguments for the authorities to restrict the ECMO procedure to only one centre. The centralisation of the ECMO procedure implies that patients generally are transferred to the Rikshospitalet University Hospital from the other centres. In some cases, the Rikshospitalet's ECMO team travels to other centres to stabilise the patient before transfer to the Rikshospitalet. In addition to the cost argument, it is believed that a certain number of treatments per year are required to obtain and maintain the skills of the ECMO team. We are, however, unaware of any studies analysing the relationship between volume, cost and quality for this particular procedure.
Finally, two methodological issues related to the cost analysis are worth mentioning. First, in our study, extracting ICU-and ECMO-specific costs was a problem because it also included the other procedures performed by specialists from several departments during ICU stays. Second, our results are based on data from a single centre, and opportunities for generalisations are, of course, restricted. Nevertheless, the identification of costs and cost drivers for the ECMO procedure presents essential information to both clinicians and hospital managements.
